The Series A round was led by Atomico with participation from Index Ventures, Norrsken VC and Daphni.
"Invention is how we solve humanity’s biggest challenges, yet the systems that protect those ideas are decades out of date. AI will redefine how global organisations innovate over the next five years, turning IP from a cost centre into a growth driver. The companies that adopt Ankar now will shape the future of innovation."
The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
"Refractory epilepsy is a devastating condition causing unpredictable and life-threatening seizures, and affecting millions of patients worldwide. Our novel gene therapy EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration. In doing so, it will change the way refractory epilepsy has been treated for decades. We are proud to have the support of such high calibre investors as we progress into clinical trials."
The Cambridge startup secured backing from National Grid Partners and Gresham House Ventures to scale its distributed quantum computing architecture.
"When we launched seven years ago, very few were thinking about networked or distributed quantum computing as a strategy for scaling, but we saw it as one of the most urgent and challenging outstanding problems in the industry, and set out to solve it. We’ve made great strides in shaping the market and the technology since then."